Clinical Chemistry

Clin Chem. 2025 Aug 22:hvaf092. doi: 10.1093/clinchem/hvaf092. Online ahead of print. ABSTRACT BACKGROUND: Population-wide reference intervals (RIpop) are commonly used in laboratory medicine but may not reflect an individual’s tightly regulated homeostatic interval. Personalized reference intervals (RIper) could enhance diagnostic precision by accounting for individual variability. A parametric empirical Bayes (PEB) framework stabilizes individual estimates … Read more

Clin Chem. 2025 Aug 21:hvaf093. doi: 10.1093/clinchem/hvaf093. Online ahead of print. ABSTRACT BACKGROUND: Next-generation sequencing for hepatitis B virus (HBV) and cytomegalovirus (CMV) antiviral drug resistance (AVDR) testing improves the sensitivity of variant detection, but availability of bioinformatics and analytical pipelines are key barriers to implementation. METHODS: Plasma was extracted on MagNA Pure 24 (Roche … Read more

Clin Chem. 2025 Aug 12:hvaf082. doi: 10.1093/clinchem/hvaf082. Online ahead of print. ABSTRACT BACKGROUND: There is increasing interest in the use of circulating cell-free RNA (cfRNA) in plasma as an analyte for diagnosing and monitoring disease. While it is known that cfRNA can also be isolated from urine, the diagnostic potential of urine cfRNA, particularly relative … Read more

Clin Chem. 2025 Aug 8:hvaf090. doi: 10.1093/clinchem/hvaf090. Online ahead of print. ABSTRACT BACKGROUND: Implementation of blood group genotyping has offered substantial benefits in transfusion medicine. However, the complex molecular basis of Rh antigen expression and a high degree of sequence homology between RHD and RHCE have long limited the accuracy of blood group genotyping, highlighting … Read more

Clin Chem. 2025 Aug 7:hvaf095. doi: 10.1093/clinchem/hvaf095. Online ahead of print. NO ABSTRACT PMID:40795262 | DOI:10.1093/clinchem/hvaf095

Clin Chem. 2025 Aug 7:hvaf085. doi: 10.1093/clinchem/hvaf085. Online ahead of print. ABSTRACT BACKGROUND: Hemophilia A and B are X-linked coagulation disorders characterized by low or dysfunctional Factor VIII (FVIII) or IX (FIX), respectively. Currently, hemophilia A and B are treated by FVIII/FIX replacement therapy with plasma-derived or recombinant products or by FVIII-mimetic agents (e.g., emicizumab). … Read more

Clin Chem. 2025 Aug 1;71(8):829-831. doi: 10.1093/clinchem/hvaf079. NO ABSTRACT PMID:40746190 | DOI:10.1093/clinchem/hvaf079

Clin Chem. 2025 Aug 1;71(8):835-839. doi: 10.1093/clinchem/hvaf028. NO ABSTRACT PMID:40746189 | DOI:10.1093/clinchem/hvaf028

Clin Chem. 2025 Aug 1;71(8):840-841. doi: 10.1093/clinchem/hvaf069. NO ABSTRACT PMID:40746188 | DOI:10.1093/clinchem/hvaf069

Clin Chem. 2025 Aug 1;71(8):839-840. doi: 10.1093/clinchem/hvaf042. NO ABSTRACT PMID:40746187 | DOI:10.1093/clinchem/hvaf042